KYMR
Kymera Therapeutics, Inc. (KYMR) Scenario Analysis Analysis (2026)
Overall Score
Base Case
KYMR remains a high-burn, pre-profitability story with negative TTM operating cash flow and free cash flow, but it still holds a strong liquidity cushion with a current ratio of 9.83x and cash per share of 7.04.
Valuation remains highly stretched on sales at 89.13x EV/Sales TTM, implying the market is still pricing in substantial future growth and/or margin expansion.
Bull Case
The balance sheet remains resilient with low leverage (debt-to-equity 0.05x, net debt-to-EBITDA 0.14x) and ample working capital, which supports continued investment in the pipeline.
If revenue scales meaningfully from the current low base, the operating leverage potential is significant given the large negative margins and high R&D intensity.
Bear Case
The company is still deeply unprofitable, with negative ROE (-21.5%), ROIC (-22.1%), and operating margin (-3.34%), so execution risk remains high.
The valuation leaves little room for disappointment, as EV/Sales near 89x and negative cash flow multiples indicate the stock is highly sensitive to any slowdown in growth or pipeline setbacks.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Kymera Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

